Protagenic Therapeutics granted new patent in Japan for modified stilbenoid
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Patent Grant Announcement: Protagenic Therapeutics received a patent (JP 7714571B) from the Japanese Patent Office on July 18, 2025, which is valid until March 31, 2041, covering a modified stilbenoid for treating epilepsy and seizures.
Company's Future Plans: The COO of Protagenic expressed optimism about the patent's significance for the company's pipeline and indicated intentions to seek similar patents in other regions.
Analyst Views on PTIX
About PTIX
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
